Business Context and Reporting Period
Company: Omeros Corporation
Filing Type: Form 8-K (Current Report)
Date of Report: November 10, 2009
Event: Entry into a Material Definitive Agreement (First Amendment of Exclusive Technology Option Agreement).
Omeros Corporation amended its September 4, 2008 agreement with Patobios Limited and others regarding an exclusive option to purchase assets related to a G protein-coupled receptor (GPCR) assay technology.
Key Financial Metrics and Agreement Terms
This filing details contractual obligations and potential future payments rather than historical financial performance metrics (revenue, profit, cash flow) for a reporting period.
- Total Purchase Price: Approximately $10.8 million CAD ($7.8 million CAD cash + $3.0 million CAD in Omeros common stock).
- Historical Option Fees Paid: $200,000 CAD (Sept 2008) and $522,000 CAD (June 2009).
- De-Orphanization Milestone Payment: $500,000 CAD (credited against the cash portion of the purchase price).
- Extension Fee (Second Option Period): $108,333 CAD due by December 4, 2009.
- Third-Party License Proceeds: Omeros must pay Patobios 60% of proceeds from licensing up to three de-orphanized GPCRs to third parties (credited against the purchase price).
Material Changes Versus Prior Agreement
The November 10, 2009 amendment introduces significant changes to the original September 2008 agreement:
- De-Orphanization Rights: Omeros now has a limited right to de-orphanize orphan GPCRs without immediately triggering Patobios' right to force a purchase of the assets.
- Screening Limits: Omeros may screen orphan GPCRs in sets of five. Screening additional sets requires Patobios' consent if at least three GPCRs are de-orphanized.
- Licensing Flexibility: Omeros may license, partner, or assign rights for up to three de-orphanized GPCRs to third parties (subject to approval).
- Termination Restrictions: Omeros may no longer terminate the agreement for convenience during an option period for which a fee has been paid; fees are non-refundable except in cases of breach.
- Automatic Exercise: Unless terminated before December 4, 2009, Omeros is required to exercise the option for the Third Option Period (starting Jan 4, 2010) and pay the associated fee.
- Fee Adjustments: The Third Option Period fee is reduced to $541,667 CAD (from $650,000 CAD) if the Second Option Period is extended. A new Fourth Option Period (ending Dec 4, 2010) is available for a $500,000 CAD fee.
Outlook, Risks, and Contingencies
- Trigger for Full Purchase: Omeros is required to purchase the assets for the full $10.8 million CAD once the sum of Third-Party License proceeds, specific government/non-profit funding, and the $500,000 CAD milestone payment reaches $5.135 million CAD.
- Proceeds Sharing: If the agreement is terminated prior to purchase, proceeds from Third-Party Licenses will be shared equally between Patobios and Omeros.
- Timeline Risk: Omeros faces a mandatory obligation to extend the option period into the Third Option Period unless the agreement is terminated by December 4, 2009.
Important Facts for Investor Verification
- Verify the current status of the "De-Orphanization Milestone" and whether the $500,000 CAD payment has been triggered.
- Confirm the exact date and amount of the $108,333 CAD extension fee payment due by December 4, 2009.
- Monitor whether Omeros has de-orphanized three or more GPCRs, which would restrict further screening without consent.
- Review the calculation of the $5.135 million CAD threshold to determine the likelihood of a mandatory full asset purchase in the near term.
- Check for any announcements regarding Third-Party Licenses that would trigger the 60% royalty payment to Patobios.